Announcement

Collapse
No announcement yet.

Cardiol Young . Cyclosporin for treatment of refractory multisystemic inflammatory syndrome in a child

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Cardiol Young . Cyclosporin for treatment of refractory multisystemic inflammatory syndrome in a child


    Cardiol Young


    . 2022 Sep 2;1-3.
    doi: 10.1017/S1047951122002748. Online ahead of print.
    Cyclosporin for treatment of refractory multisystemic inflammatory syndrome in a child


    Luisa Berenise Gámez-González 1 , Hiromichi Hamada 2 , Marco Antonio Yamazaki-Nakashimada 3



    Affiliations

    Abstract

    Multisystemic inflammatory syndrome in children is an inflammatory condition with multiorgan dysfunction that manifest late in the course of Severe acute respiratory syndrome coronavirus 2 infection. We present a 12-year-old boy with a history of fever, vomiting, diarrhoea, and abdominal pain. He developed shock with ventricular dysfunction and pericardial effusion. He was diagnosed with multisystemic inflammatory syndrome in children and treatment with intravenous immunoglobulins, corticosteroids, and tocilizumab proved to be ineffective. Eventually, the patient responded to cyclosporin-A treatment. Multisystemic inflammatory syndrome in children has been treated with immunoglobulins and glucocorticoids and in refractory cases biologics and cyclosporin-A have been used. Intravenous and oral cyclosporin-A seems to be a safe and effective alternative treatment for refractory multisystemic inflammatory syndrome in children patients.

    Keywords: COVID-19; Kawasaki disease; MIS-C; SARS-CoV2; cyclosporine.

Working...
X